No Data
Sutro Biopharma Price Target Maintained With a $8.00/Share by Wedbush
Sutro Biopharma Price Target Maintained With a $8.00/Share by Wedbush
Express News | HC Wainwright & Co. Reiterates Buy on Sutro Biopharma, Maintains $12 Price Target
Sutro Biopharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 169.66% HC Wainwright & Co. → $12 Reiterates Buy → Buy 05/08/2024 169.66% B of A Securities → $
Buy Rating on Sutro Biopharma: Promising Trials and Market Expansion Potential for Luvelta
Sutro Biopharma's Luvelta: A Promising Candidate in PROC With Expanding Clinical Trials and FDA Accelerated Approval Potential
Sutro Biopharma Q1 Loss Widens, Revenue Rises
Sutro Biopharma (STRO) reported a Q1 net loss late Monday of $0.95 per diluted share, compared with $0.85 loss a year ago. Analysts polled by Capital IQ expected a loss of $0.93. Revenue for the quart